ARS Pharmaceuticals (SPRY) Receivables - Other (2021 - 2025)

ARS Pharmaceuticals (SPRY) has 5 years of Receivables - Other data on file, last reported at $4.3 million in Q3 2025.

• For the quarter ending Q3 2025, Receivables - Other rose 3109.77% year-over-year to $4.3 million; the trailing twelve-month figure through Sep 2025 stood at $4.3 million (up 3109.77% YoY), and the FY2024 full-year result was $1.2 million, up 88.96% from the prior year.
• Receivables - Other advanced to $4.3 million in Q3 2025, from $2.0 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $4.3 million in Q3 2025 to a low of $122000.0 in Q2 2024.
• A 5-year average of $839538.5 and a median of $307000.0 in 2023 frame the typical range for Receivables - Other.
• Across the five-year window, Receivables - Other slumped 65.04% in 2024 and soared 3109.77% in 2025, its largest moves.
• Tracing SPRY's Receivables - Other over 5 years: stood at $159000.0 in 2021, then soared by 33.96% to $213000.0 in 2022, then jumped by 206.1% to $652000.0 in 2023, then soared by 88.96% to $1.2 million in 2024, then soared by 246.51% to $4.3 million in 2025.
• Business Quant data shows SPRY's Receivables - Other at $4.3 million in Q3 2025, $2.0 million in Q2 2025, and $963000.0 in Q1 2025.